Properties (138)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:academicAdvisor |
renowned experts.
|
| gptkbp:awards |
industry recognition
various industry recognitions |
| gptkbp:budget |
available to investors
|
| gptkbp:businessModel |
research and development
biopharmaceutical development strategic partnerships. develop innovative therapies. |
| gptkbp:CEO |
Abdul_M._Mughal
|
| gptkbp:clinicalTrials |
metabolic disorders
ongoing efforts Phase 1, Phase 2, Phase 3 published in journals innovative approaches ongoing. published in scientific journals ongoing analysis Phase 1/2 early-stage INZ-701 Phase 1, Phase 2. adaptive trial designs. aim for positive results. improve patient outcomes. innovative and adaptive. new methodologies. open to eligible patients. patient-centric approach. rare metabolic diseases rare metabolic disorders. regularly communicated. to be published. to be shared with the community. multiple_sites_in_the_US various_US_sites. |
| gptkbp:collaborations |
academic institutions
|
| gptkbp:communityEngagement |
patient advocacy groups
|
| gptkbp:communityOutreach |
engagement with stakeholders.
|
| gptkbp:communityPartnerships |
with hospitals and clinics
|
| gptkbp:communitySupport |
patient communities
active in patient communities. |
| gptkbp:corporateSocialResponsibility |
focus on long-term impact.
to rare disease patients. |
| gptkbp:culturalHeritage |
innovation-driven.
|
| gptkbp:deathDate |
INZ-701
|
| gptkbp:drugInterdiction |
strategic planning
|
| gptkbp:employeeCount |
growing team
|
| gptkbp:financialPerformance |
publicly reported
patents on drug formulations reported quarterly. tracked on financial markets tracked on stock exchanges transparency and communication. |
| gptkbp:financials |
quarterly and annual reports
|
| gptkbp:focus |
rare diseases
|
| gptkbp:founded |
2019
|
| gptkbp:funding |
venture capital
|
| gptkbp:futurePlans |
expand into new therapies
advancing clinical trials |
| gptkbp:hasPopulation |
rare disease patients
specific rare disease patients |
| gptkbp:hasPrograms |
experts in rare diseases
renowned scientists |
| gptkbp:hasResearchInterest |
conducted regularly
rare disease landscape. |
| gptkbp:headCoach |
gptkb:Dr._Jane_Smith
gptkb:Dr._John_Doe |
| gptkbp:headquarters |
gptkb:Boston,_Massachusetts
|
| gptkbp:healthcare |
in clinical trials
collaboration with advocacy groups. focus on patient needs. |
| gptkbp:historicalEvent |
founded in 2019.
|
| gptkbp:historicalResearch |
with universities
biopharmaceutical research expanding therapeutic areas. |
| https://www.w3.org/2000/01/rdf-schema#label |
Inozyme Pharma
|
| gptkbp:impact |
enzyme replacement.
|
| gptkbp:industry |
patient-first approach.
|
| gptkbp:investmentFocus |
available online
institutional and retail investors institutional investors public disclosures engaged with shareholders |
| gptkbp:keyEvent |
successful funding rounds
|
| gptkbp:leadership |
experienced professionals
experienced executives transformative therapies. |
| gptkbp:leads |
INZ-701
|
| gptkbp:manufacturer |
innovative therapies for rare diseases.
integrity and innovation. |
| gptkbp:market |
global market
emerging leader in rare diseases. global rare disease market |
| gptkbp:marketSegment |
focus on unmet medical needs
targeted therapies. |
| gptkbp:mission |
transform the lives of patients with rare diseases.
|
| gptkbp:parent_company |
achieved significant funding.
open communication with investors. |
| gptkbp:partnerships |
research institutions
various pharmaceutical companies biopharmaceutical companies |
| gptkbp:productionCompany |
leading in rare disease therapies.
|
| gptkbp:products |
ongoing
INZ-701 and others |
| gptkbp:regulatoryCompliance |
investigational
FDA_submissions adherence_to_FDA_guidelines. |
| gptkbp:research |
grants and investments
venture capital and grants. |
| gptkbp:research_areas |
genetic disorders
metabolic disorders aims for breakthroughs. |
| gptkbp:researchAreas |
enzyme replacement therapy
metabolic diseases. |
| gptkbp:researchFocus |
enzyme replacement therapy
|
| gptkbp:researchInterest |
peer-reviewed articles
with biotech firms commitment to ethical standards. advancing rare disease treatments. collaborative research findings cutting-edge technologies. develop effective therapies. enhance scientific knowledge. leading biopharmaceutical companies. peer-reviewed journals. with leading universities. |
| gptkbp:stockSymbol |
INZY
|
| gptkbp:strategicGoals |
expand pipeline
expansion of research. |
| gptkbp:sustainabilityPractices |
ethical research practices
|
| gptkbp:teamAchievements |
successful drug development.
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:tributaryOf |
multiple drug candidates
|
| gptkbp:type |
public company
|
| gptkbp:updates |
regular communications
regular communications. |
| gptkbp:website |
www.inozyme.com
|